⌘K
Loading ticker…
As of 2026-08-24, Bioventus Inc. Class A Common Stock (BVS) has a 3-month relative strength percentile of 94 and a leadership percentile of 98 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 72. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.6%, relative volume 0.77×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BVS is in a stage 2 uptrend, week 8. Currently in a 13-day base; basing ADR 5.4% (broad 5.1%). VCP detected: no. RS line below base-start high. Distance from 50d / 200d: 17.1% / 49.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
BVS is held by 20 ETFs as of May 2026. Top owner: AVUV at 0.03% weight, $8M notional. Top 3 carry $12M.
Held by 40 ETFs · $56M across latest filings · largest weight 0.86% (FDLS).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| AVUVAvantis U.S. Small Cap Value ETF | 0.03% | $8M | — |
| VTWO | 0.01% | $2M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| FDLS | 0.86% | $2M | new |
| VHTVanguard Health Care ETF | 0.01% | $1M | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| VFMF | 0.13% | $837K | +0.03 pp |
| AVSC | 0.02% | $541K | — |
| VFVA | 0.06% | $488K | — |
| VTWG | 0.02% | $375K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $233K | — |
Showing 10 of 20 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BVS Jan avg: -8.56% median: -7.97% win: 50% σ: 15.11% n: 4 2022-04-12 → 2026-07-31 | BVS Feb avg: 5.25% median: 7.68% win: 75% σ: 7.07% n: 4 2022-04-12 → 2026-07-31 | BVS Mar avg: -10.81% median: -2.89% win: 50% σ: 27.52% n: 4 2022-04-12 → 2026-07-31 | BVS Apr avg: -9.64% median: -6.74% win: 20% σ: 12.76% n: 5 2022-04-12 → 2026-07-31 | BVS May avg: 38.75% median: -11.35% win: 40% σ: 80.69% n: 5 2022-04-12 → 2026-07-31 | BVS Jun avg: -5.02% median: 2.16% win: 60% σ: 17.33% n: 5 2022-04-12 → 2026-07-31 | BVS Jul avg: 21.93% median: 24.49% win: 80% σ: 14.80% n: 5 2022-04-12 → 2026-07-31 | BVS Aug avg: 10.60% median: 6.47% win: 50% σ: 24.54% n: 4 2022-04-12 → 2026-07-31 (current) | BVS Sep avg: -0.82% median: -6.29% win: 25% σ: 13.35% n: 4 2022-04-12 → 2026-07-31 | BVS Oct avg: 10.20% median: 13.29% win: 75% σ: 8.31% n: 4 2022-04-12 → 2026-07-31 | BVS Nov avg: -15.59% median: -1.10% win: 50% σ: 41.65% n: 4 2022-04-12 → 2026-07-31 | BVS Dec avg: 12.26% median: 14.89% win: 50% σ: 24.28% n: 4 2022-04-12 → 2026-07-31 |